<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430820</url>
  </required_header>
  <id_info>
    <org_study_id>P060201</org_study_id>
    <nct_id>NCT00430820</nct_id>
  </id_info>
  <brief_title>Discovery of New Circulating Biomarkers of Coronary Atherosclerosis</brief_title>
  <official_title>Discovery of New Circulating Biomarkers of Coronary Atherosclerosis Using Differential Proteomics: the BIOmarkers of CORonary Events (BIOCORE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that differential proteomic techniques can be used to discover new
      circulating biomarkers of coronary atherosclerosis in the blood of patients suffering from
      coronary artery disease (either stable or unstable) who will be compared to a group of
      patients without coronary artery disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Our hypothesis is that coronary atherosclerosis induces both quantitative and
      qualitative modifications of circulating proteins, which can be captured by a differential
      proteomic approach applied to serum or plasma samples. Identification of such modifications
      in the circulating blood of patients with coronary artery disease (versus patients without
      coronary artery disease) and/or of patients with acute coronary syndromes (versus stable
      coronary artery disease) may lead to discovery of new biomarkers of coronary atherosclerosis
      and of atherosclerotic plaque vulnerability.

      Objectives:

      Primary objective: Identification of new circulating biomarkers of stable and unstable
      coronary artery disease using a new approach of differential proteomics.

      Secondary objectives:

        -  Evaluation of the diagnostic value of these new biomarkers for the diagnosis of stable
           and unstable coronary artery disease.

        -  Comparison of the diagnostic value of these new biomarkers to the diagnostic value of 1)
           other validated biomarkers of atherosclerosis (eg, CRP, IL-6, CD40L, markers of
           leukocyte activation, …); and 2) of non-invasive measures of arterial function (eg,
           carotid artery intima-media thickness, pulse wave velocity, ankle/brachial index, …)

        -  Description of the relationship between these new biomarkers and major adverse coronary
           events (death, myocardial infarction, revascularization) during a 12-month follow-up.

      Methods:

      Uniq center, prospective study. Three groups of patients will be studied. Group 1:
      Non-ST-elevation acute myocardial infarction; Group 2: Stable coronary artery disease; Group
      3: normal coronary arteries and absence of other detectable atherosclerotic lesions.

      A new proteomic approach will be applied to serum and plasma samples obtained 1 month after
      the index hospitalisation. This approach includes 3 steps: 1) equalisation of circulating
      proteins (expose low-concentration proteins belonging to the &quot;deep-proteome&quot;); 2) Retention
      chromatography; and 3) protein separation using 2D-electrophoresis and Surface-Enhanced Laser
      Desorption/Ionisation Time-of-Flight (SELDI-TOF).

      Biomarkers with the highest diagnostic value will be subsequently identified using
      Matrix-Assisted Laser Desorbtion/Ionisation Time-of-Flight (MALDI-TOF) and tandem mass
      spectrometry (MS/MS).

      Perspectives:

      Validation of the diagnostic and prognostic values of the new biomarkers discovered and
      identified using the proteomic approach described above will require development of more
      straightforward measurement techniques (eg, ELISA), which will be used prospectively or
      retrospectively in other cohorts of patients with coronary artery disease. Basic studies will
      be performed in parallel, so as to better understand the role of these new biomarkers in the
      pathophysiology of atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndromes</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>per intervention</intervention_name>
    <description>per intervention</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biomarqueurs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Identification de nouveaux marqueurs circulants de l'athérosclérose coronarienne et de ses
        complications par une nouvelle technique de protéomique différentielle.

        Identification of new parqueurs circulated in coronary artheriosclerosis and complications
        of the new differentiel technicology
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1 (Non-ST-elevation acute myocardial infarction) :

               -  Chest pain less than 48 hours before admission,

               -  And modifications of ST-T (no persistent ST elevation) on 12-lead EKG,

               -  And elevation of troponin-I &gt;1xN,

               -  And presence of ≥1 de novo stenosis(es) &gt;50% located on ≥1 native coronary
                  artery(ies) and successfully treated using percutaneous coronary intervention and
                  stenting.

          -  Group 2 (Stable coronary artery disease) :

               -  Documented myocardial ischemia (stable angina or positive stress test)

               -  And presence of ≥1 de novo stenosis(es) &gt;50% located on ≥1 native coronary
                  artery(ies) and successfully treated using percutaneous coronary intervention and
                  stenting.

          -  Group 3 (Normal coronary arteries) :

               -  No history of coronary artery disease, neurovascular disease or peripheral artery
                  disease,

               -  And normal coronary angiography performed because of suspected coronary artery
                  disease

               -  And absence of significant functional or anatomic abnormalities suggestive of
                  atherosclerosis on non-invasive arterial studies (measurements of intima-media
                  thickness, pulse wave velocity, ankle-brachial index, …).

        Exclusion Criteria:

          -  Group 1 :

               -  Preexisting EKG abnormalities (including left bundle branch block) precluding
                  accurate assessment of ST-T changes

          -  Group 2 :

               -  History of acute coronary syndrome

          -  Groups 1 and 2:

               -  Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is
                  located in a bypass graft.

          -  All groups :

               -  Heart failure (NYHA class ≥II)

               -  Left ventricular ejection fraction &lt;50%

               -  Severe valvular heart disease requiring surgical or percutaneous therapy

               -  History of autoimmune, inflammatory or neoplasia diseases ; or infectious disease
                  in the month before admission

               -  Life expectancy &lt; 1 year

               -  Age &lt;18 years or &gt;80 years

               -  Current pregnancy or breast-feeding

               -  Homeless or travelers who may not be followed-up

               -  Refusal to sign the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent FELDMAN, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Hopital Bichat, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Duran MC, Mas S, Martin-Ventura JL, Meilhac O, Michel JB, Gallego-Delgado J, Lázaro A, Tuñon J, Egido J, Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003 Jun;3(6):973-8.</citation>
    <PMID>12833522</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tuñón J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004 Oct 12;110(15):2216-9. Epub 2004 Jul 12.</citation>
    <PMID>15249501</PMID>
  </results_reference>
  <results_reference>
    <citation>Vivanco F, Martín-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Dardé VM, Mas S, Meilhac O, Michel JB, Tuñón J, Egido J. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res. 2005 Jul-Aug;4(4):1181-91. Review.</citation>
    <PMID>16083268</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanco-Colio LM, Martín-Ventura JL, Vivanco F, Michel JB, Meilhac O, Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res. 2006 Oct 1;72(1):18-29. Epub 2006 May 24. Review.</citation>
    <PMID>16814757</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yannick Vacher</name_title>
    <organization>Department Clinical Research of Developppement</organization>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Mass spectrometry</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Acute coronary syndromes</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

